Inserting Prevnar 13 Into Adult Treatment Guidelines Could Raise Questions For Practitioners
Uncertainty about the effect of Pfizer’s vaccine in patients that have already had Merck’s Pneumovax 23 could cause problems.
You may also be interested in...
Advisory committee votes 14-1 in favor of effectiveness and safety in adults 50 and older.
CDER Director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.
Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.